Experts discuss the current research on the use of digital therapeutics for managing chronic pain in rheumatic disease.

Unfortunately, in up to 30–40% of patients that chronically consume opioids, opioid-induced hyperalgesia occurs. [59] This condition refers to a generalized and increasing pain sensitivity that ...

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

Journavx, a new non-opioid pain medication, offers a safer alternative for managing acute pain while reducing the risk of ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

Black individuals in the U.S. with serious illnesses receive disproportionately poor pain management and health care ...

But there is growing awareness of the complexity of pain and the need for tailored management. Increasingly, patients are turning to pain clinics that offer that possibility: There, they can ...

Integrating lifestyle care into low back pain management resulted in greater improvements in disability, weight loss and ...

Aims: The use of medication in pain management currently involves empirical ... the clinical effectiveness of genotyping chronic pain patients on analgesic therapy. It was hypothesized that ...

People undergoing hemodialysis treatment for kidney failure often experience chronic pain related to their condition, but it ...

For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...